Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: Current status in Japan

Internal Medicine

Volumn 52, Issue 24, 2013, Pages 2701-2706

  Sato, Akira ^a   Sata, Michio ^b   Ikeda, Kenji ^c   Kumada, Takashi ^d   Izumi, Namiki ^e   Asahina, Yasuhiro ^e   Osaki, Yukio ^f   Chayama, Kazuaki ^g   Kaneko, Shuichi ^h   Sakai, Akito ^h   Onji, Morikazu ⁱ   Hiasa, Yoichi ⁱ   Omura, Takumi ^j   Ozeki, Itaru ^j   Yokosuka, Osamu ^k   Shiina, Shuichiro ^l   Itsubo, Mariko ^m   Nishiguchi, Shuhei ⁿ   Hirano, Katsuharu ^o   Ide, Tatsuya ^b   Sakisaka, Shotaro ^p   Yamasaki, Takahiro ^q   Hidaka, Isao ^q   Tanaka, Masatoshi ^r   Ryang Kim, Soo ^s   Ichida, Takafumi ^o   more..

^a ST MARIANNA UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d OGAKI MUNICIPAL HOSPITAL   (Japan)

^e MUSASHINO RED CROSS HOSPITAL   (Japan)

^f OSAKA RED CROSS HOSPITAL   (Japan)

^g HIROSHIMA UNIVERSITY   (Japan)

^h KANAZAWA UNIVERSITY   (Japan)

ⁱ EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j Sapporo Kosei General Hospital   (Japan)

^k CHIBA UNIVERSITY   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

^m JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ HYOGO COLLEGE OF MEDICINE   (Japan)

^o JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^p FUKUOKA UNIVERSITY   (Japan)

^q YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^r KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^s KOBE ASAHI HOSPITAL   (Japan)

more..

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Interferon; Sustained viral response

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; INTERFERON;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER INCIDENCE; DIABETES MELLITUS; DISEASE ERADICATION; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84890477161     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.1180     Document Type: Article

References (32)

1. World Health Organization. Global Alert and Response (GAR): Hepatitis C. 2012. Accessed 27 May 2013. http://www.who.Int/mediacentre/factsheets/fs164/en/index.html
2. Center for Cancer Control and Information Services, National Cancer Center, Japan. Cancer Statistics in Japan-2011. Accessed 27 May 2013. http://ganjoho.jp/pro/statistics/en/backnumber/2012_en.html
3. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan Hepatol Res 37: S95-S100, 2007.
4. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan Ann Intern Med 131: 174-181, 1999.
5. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 28: 930-938, 1998.
6. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18: 47-53, 1993.
7. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47: 131-136, 2000.
8. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis C: a long term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29: 1124-1130, 1999.
9. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45: 579-587, 2007.
10. Watanabe S, Enomoto N, Koike K, et al. Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. Hepatol Res 41: 955-964, 2011.
11. Mashitani T, Yoshiji H, Yamazaki M, et al. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. Cases J 2: 18, 2009.
12. Saito M, Seo Y, Yano Y, et al. Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review. Clin J Gastroenterol 5: 119-126, 2012.
13. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 31: 552-558, 1996.
14. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27: 1394-1402, 1998.
15. Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 101: 1616-1622, 2004.
16. Iwasaki Y, Takaguchi K, Ikeda H, et al. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 24: 603-610, 2004.
17. Tokita H, Fukui H, Tanaka A, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 20: 752-758, 2005.
18. Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 40: 148-156, 2005.
19. Tanaka A, Uegaki S, Kurihara H, et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 13: 5180-5187, 2007.
20. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 27: 186-191, 2007.
21. Hirakawa M, Ikeda K, Arase Y, et al. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med 47: 1637-1643, 2008.
22. The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan, Circ J 66: 987-992, 2002.
23. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2009 update. Hepatol Res 40 (Suppl 1): S2-S144, 2010.
24. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 127 (Suppl 1): S87-S96, 2004.
25. Ohishi W, Fujisawa S, Cologne JB, et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev 17: 846-854, 2008.
26. Ohki T, Tateishi R, Sato T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 6: 459-464, 2008.
27. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135: 111-121, 2008.
28. Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 57: 964-973, 2013.
29. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52: 518-527, 2010.
30. Nagaoki Y, Aikata H, Miyaki D, et al. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol 46: 799-808, 2011.
31. Kurosaki M, Hiramatsu N, Sakammoto M, et al. Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. J Hepatol 56: 602-608, 2012.
32. Asahina Y, Tsuchiya K, Nishimura T, et al. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 58: 1253-1262, 2013.